CapsoVision, Inc. (CV)

Market Cap	299.53M
Revenue (ttm)	13.55M +15.3%
Net Income	-25.32M
EPS	-1.03
Shares Out	49.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,660
Open	5.42
Previous Close	5.40
Day's Range	5.41 - 6.10
52-Week Range	3.43 - 15.37
Beta	n/a
Analysts	Buy
Price Target	10.00 (+66.39%)
Earnings Date	May 20, 2026

About CV

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as a...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 2, 2025
• Employees: 99
• Stock Exchange: NASDAQ
• Ticker Symbol: CV
• Website: https://capsovision.com

Financial Performance

In 2025, CapsoVision's revenue was $13.55 million, an increase of 15.29% compared to the previous year's $11.76 million. Losses were -$25.32 million, 27.2% more than in 2024.

Analyst Summary

According to one analyst, the rating for CV stock is "Buy" and the 12-month stock price target is $10.0.

Price Target

$10.0

(66.39% upside)

Analyst Consensus: Buy